GlassScriptPhysician profile
Brian A Akrami
NPI 1750320958
$1,486.03
in general payments reported to CMS, 2019-2025
27 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.73 · 2020: $59.38 · 2021: $273 · 2022: $228 · 2023: $189 · 2024: $522 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $258.39 | 2022-2025 | Aveir, Amplatzer Amulet |
| Medtronic, INC. | $164.21 | 2021-2024 | Cardioblate Cryoflex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.60 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $143.03 | 2021-2024 | Ozempic, Rybelsus, Saxenda |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Pfizer INC. | $82.72 | 2023-2025 | |
| Lilly USA, LLC | $80.83 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $63.15 | 2019-2024 | Watchman Access System, Watchman Flx, Rezum Generator |
| Dexcom, INC. | $41.65 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $36.81 | 2022-2025 | Repatha |
| Ironshore Pharmaceuticals INC. | $32.54 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $30.69 | 2020-2021 | |
| Kestra Medical Technology Services, INC. | $25.38 | 2025 | Assure Wcd |
| Mannkind Corporation | $23.46 | 2024 | |
| Abbvie INC. | $23.37 | 2023 | Synthroid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $22.16 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.51 | 2024 | |
| Sumitomo Pharma America, INC. | $21.48 | 2025 | Myfembree |
| Vital Connect, INC | $21.46 | 2024 | Vitalpatch Rtm |
| Amarin Pharma, INC. | $21.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.10 | 2021 | |
| Eisai INC. | $19.15 | 2021 | |
| Laborie Medical Technologies Corp. | $18.89 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.29 | 2023 | Xifaxan |
| Glaxosmithkline, LLC. | $14.22 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.83 | 2019 | |
| Esperion Therapeutics, INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Akrami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.